Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pennig, J; Scherrer, P; Gissler, MC; Anto-Michel, N; Hoppe, N; Füner, L; Härdtner, C; Stachon, P; Wolf, D; Hilgendorf, I; Mullick, A; Bode, C; Zirlik, A; Goldberg, IJ; Willecke, F.
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
Sci Rep. 2019; 9(1):17937-17937
Doi: 10.1038/s41598-019-54224-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Anto Michel Nathaly
- Zirlik Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Diabetes worsens atherosclerosis progression and leads to a defect in repair of arteries after cholesterol reduction, a process termed regression. Empagliflozin reduces blood glucose levels via inhibition of the sodium glucose cotransporter 2 (SGLT-2) in the kidney and has been shown to lead to a marked reduction in cardiovascular events in humans. To determine whether glucose lowering by empagliflozin accelerates atherosclerosis regression in a mouse model, male C57BL/6J mice were treated intraperitoneally with LDLR- and SRB1- antisense oligonucleotides and fed a high cholesterol diet for 16 weeks to induce severe hypercholesterolemia and atherosclerosis progression. At week 14 all mice were rendered diabetic by streptozotocin (STZ) injections. At week 16 a baseline group was sacrificed and displayed substantial atherosclerosis of the aortic root. In the remaining mice, plasma cholesterol was lowered by switching to chow diet and treatment with LDLR sense oligonucleotides to induce atherosclerosis regression. These mice then received either empagliflozin or vehicle for three weeks. Atherosclerotic plaques in the empagliflozin treated mice were significantly smaller, showed decreased lipid and CD68+ macrophage content, as well as greater collagen content. Proliferation of plaque resident macrophages and leukocyte adhesion to the vascular wall were significantly decreased in empagliflozin-treated mice. In summary, plasma glucose lowering by empagliflozin improves plaque regression in diabetic mice.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Atherosclerosis - blood
- Atherosclerosis - drug therapy
- Atherosclerosis - etiology
- Benzhydryl Compounds - therapeutic use
- Blood Glucose - analysis
- Diabetes Mellitus, Experimental - blood
- Diabetes Mellitus, Experimental - complications
- Diabetes Mellitus, Experimental - drug therapy
- Glucosides - therapeutic use
- Male -
- Mice -
- Mice, Inbred C57BL -
- Plaque, Atherosclerotic - blood
- Plaque, Atherosclerotic - drug therapy
- Plaque, Atherosclerotic - etiology
- Sodium-Glucose Transporter 2 Inhibitors - therapeutic use